Creative Medical TechnologyCELZ
CELZ
About: Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
Employees: 4
0
Funds holding %
of 7,363 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
3.46% less ownership
Funds ownership: 5.16% [Q3] → 1.71% (-3.46%) [Q4]
20% less funds holding
Funds holding: 10 [Q3] → 8 (-2) [Q4]
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
67% less capital invested
Capital invested by funds: $214K [Q3] → $71.2K (-$143K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for CELZ.
Financial journalist opinion
Based on 3 articles about CELZ published over the past 30 days
Neutral
GlobeNewsWire
5 days ago
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds
PHOENIX, March 06, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a leading biotechnology innovator in regenerative medicine, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 837,104 shares of common stock of the Company originally issued in October 2024 at their current exercise price of $4.42 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-283091). The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $3.7 million, before deducting financial advisory fees.
Neutral
GlobeNewsWire
3 weeks ago
Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™
PHOENIX, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a pioneering biotechnology firm specializing in regenerative medicine solutions for immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced compelling mid-term follow-up data from its StemSpine® pilot study utilizing its AlloStem™ cells for the treatment of chronic lower back pain. The pilot study demonstrated a substantial reduction in opioid dependency and significant improvements in pain levels and functional mobility.
Neutral
GlobeNewsWire
4 weeks ago
Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program
Significant Efficacy and No Serious Adverse Effects Observed with CELZ-201 Significant Efficacy and No Serious Adverse Effects Observed with CELZ-201
Neutral
GlobeNewsWire
1 month ago
Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development
PHOENIX, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced an expanded agreement with Greenstone Biosciences Inc. (“Greenstone”) to leverage Artificial Intelligence (AI) in further developing its human induced pluripotent stem cell (iPSC) platform for diabetes treatment.
Neutral
GlobeNewsWire
1 month ago
Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain
PHOENIX, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative medicine, today announced promising initial data from the first cohort of its ongoing Phase 1/2 clinical trial of CELZ-201-DDT, the Company's proprietary stem cell-based therapeutic for the treatment of chronic back pain caused by degenerative disc disease (DDD).
Positive
Benzinga
3 months ago
Top 3 Real Estate Stocks That May Explode In Q4
The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.
Neutral
GlobeNewsWire
3 months ago
Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment
PHOENIX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology leader in regenerative medicine, is pleased to announce the successful completion of an independent interim safety review by the Data Safety Monitoring Board (DSMB) for its ADAPT clinical trial. The trial evaluated CELZ-201, a novel therapeutic perinatal tissue derived cell product, designed to treat chronic lower back pain associated with degenerative disc disease.
Neutral
GlobeNewsWire
7 months ago
Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program
PHOENIX, July 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has initiated its planned program to diagnose and treat patients exposed to biological and chemical weapons by combining Artificial Intelligence (AI) with the Company's proprietary human induced pluripotent stem cells (“iPSC”). This iPSC clinical line is part of the Company's iPSCelz® program.
Neutral
GlobeNewsWire
8 months ago
Creative Medical Technology Holdings Provides Corporate Update
PHOENIX, July 10, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update highlighting recent developments of note.
Neutral
GlobeNewsWire
8 months ago
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin
PHOENIX, June 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has successfully generated human induced pluripotent stem cells (iPSC)-derived Islet Cells that produce human insulin.
Charts implemented using Lightweight Charts™